You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BB MEDICAL SURGICAL, INC. Topic: NICHD
PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic FilariasisSBC: NANOCOMPOSIX, INC. Topic: NIAID
Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Renova Therapeutics, Inc. Topic: NHLBI
ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Sersense Inc Topic: NICHD
ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBI
Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Vova Ida, LLC Topic: 999
SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinomaSBC: Avenzoar Pharmaceuticals, Inc. Topic: 102
ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: WEST FACE MEDICAL DEVICES, INC. Topic: NIBIB
DESCRIPTION provided by applicant This Phase I STTR Grant Proposal requests $ support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K Wang PhD and his laboratory at the University of Washington Utilizing optical coherence tomography OCT the patented OCT Adaptor USPTO Pats provides r ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: N
DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
SBC: ELGAVISH PARAMAGNETICS, INC. Topic: NHLBI
DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health